NCT07158268View on ClinicalTrials.gov

A Phase 2 Study of HSK47388 Tablets to Evaluate the Efficacy and Safety in Patients With Moderate-to-Severe Plaque Psoriasis

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

220

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

December 20, 2026

Study Completion Date

January 17, 2027

Conditions

Plaque Psoriasis

Interventions

DRUG

HSK47388

HSK47388 tablets will be administered orally, once a day

All Listed Sponsors

lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY